Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
EMD Serono |
---|---|
Information provided by: | EMD Serono |
ClinicalTrials.gov Identifier: | NCT00328926 |
To confirm the efficacy of the 75 IU dose of Luveris® compared to placebo when administered concomitantly with follitropin alfa for induction of clinical pregnancy in women with hypogonadotropic hypogonadism and profound LH deficiency (LH <1.2 IU/L), and to study the efficacy of a lower dose (25 IU) of Luveris® compared to placebo when administered concomitantly with follitropin alfa for induction of follicular development in women with hypogonadotropic hypogonadism and profound LH deficiency (LH <1.2 IU/L).
Condition | Intervention | Phase |
---|---|---|
Hypogonadotropic Hypogonadism |
Drug: Placebo Drug: lutropin alfa |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Phase IV , Multicenter, Randomized, Double-Blinded, Clinical Trial to Confirm the Efficacy of the 75 IU Dose of Luveris® vs. Placebo When Administered With Follitropin Alfa for Induction of Follicular Development and Pregnancy in Hypogonadotropic Hypogonadal Women With Profound LH Deficiency, as Defined by a Baseline LH Level <1.2 IU/L. |
Estimated Enrollment: | 234 |
Study Start Date: | October 2005 |
Estimated Study Completion Date: | December 2011 |
Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator
Gonal-f® + a placebo
|
Drug: Placebo
Subcutaneous injection once daily until criteria for ovulation triggering is met (21 day max)
|
2: Experimental
Gonal-f® + lutropin alfa 25 IU
|
Drug: lutropin alfa
Once daily Subcutaneous injection until criteria for ovulation triggering is met (21 day max)
|
3
Gonal-f® + lutropin alfa 75 IU
|
Drug: lutropin alfa
Once daily subcutaneous injection until criteria for ovulation triggering is met (21 day max)
|
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
FSH: <5 IU/L LH: <1.2 IU/L
Exclusion Criteria:
Contact: U.S. Medical Information | 888-275-7376 |
United States, Massachusetts | |
U.S. Medical Information | Recruiting |
Rockland, Massachusetts, United States, 02370 |
Study Director: | Donald R Tredway, M.D., PhD | EMD Serono |
Responsible Party: | EMD Serono, Inc. ( Stephanie Ruhl, Clinical Trial Manager ) |
Study ID Numbers: | 26109 |
Study First Received: | May 20, 2006 |
Last Updated: | January 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00328926 |
Health Authority: | United States: Food and Drug Administration |
Hypogonadotropic Hypogonadism (LH <1.2 IU/L) |
Hypogonadism Gonadal Disorders Endocrine System Diseases Endocrinopathy Follicle Stimulating Hormone |